Loading provider…
Loading provider…
Medical Oncology Physician in Orange, CA
NPI: 1093822017Primary Practice Location
UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER
101 The City Dr S, Orange, CA
Primary Employer
UCI Department of Medicine
medschool.uci.edu
HQ Phone
Get MD Warren's Phone Numberphone_androidMobile
Get MD Warren's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1987 - 2027

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Cedars-Sinai Medical Center
Residency • Internal Medicine
1986 - 1990
Internship • Internal Medicine
1986 - 1987
Chicago Medical School at Rosalind Franklin University of Medicine and Science
Medical School
Until 1986
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 101 | 293 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 36 | 36 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 32 | 41 |
| 4 | 99441Physician telephone patient service, 5-10 minutes of medical discussion | 13 | 16 |
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer
Authors: Robert Morgan, Stephen Forman, Neil Kogut, George Somlo, Kim Margolin, Lucille Leong, Arturo Molina
Journal: Br J Cancer
Authors: Merry Tetef, Robert Morgan, Przemyslaw Twardowski, Yun Yen, Dean Lim, George Somlo, Kim Margolin, Lucille Leong
Journal: Cancer Chemother Pharmacol
Publication Date: 2004-06-02
Authors: Guan, Min, Su, Leila, Yuan, Yate-Ching, Li, Haiqing, Chow, Warren A
Journal: Sci Rep
Publication Date: 2015-04-16
Lead Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd
Intervention / Treatment: DRUG: SGN1
Lead Sponsor: Adaptimmune
Intervention / Treatment: BIOLOGICAL: ADP adoptive cell therapy
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Dulaglutide, DRUG: tirzepatide